重塑肿瘤免疫微环境，改善基于 CAR-T 细胞的癌症免疫治疗。
Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy.
发表日期：2024 Aug 26
作者：
Xueting Xia, Zongxin Yang, Qisi Lu, Zhenyun Liu, Lei Wang, Jinwen Du, Yuhua Li, Dong-Hua Yang, Shaojie Wu
来源：
Molecular Cancer
摘要：
在许多血液恶性肿瘤中，嵌合抗原受体 (CAR) T 细胞的过继转移已取得显着成功。尽管如此，还需要进一步改进以优化治疗效果。目前的 CAR-T 疗法对于实体瘤治疗尤其令人沮丧。肿瘤的免疫抑制微环境会影响 CAR-T 细胞，限制治疗的有效性和安全性。因此，增强CAR-T细胞浸润能力并解决肿瘤微环境内的免疫抑制反应可以增强抗肿瘤效果。具体策略包括改变CAR-T细胞结构并结合靶向治疗、放疗或化疗。总体而言，监测肿瘤微环境和 CAR-T 细胞的状态有利于进一步研究此类策略的可行性并推进 CAR-T 细胞疗法。© 2024。作者。
In many hematologic malignancies, the adoptive transfer of chimeric antigen receptor (CAR) T cells has demonstrated notable success; nevertheless, further improvements are necessary to optimize treatment efficacy. Current CAR-T therapies are particularly discouraging for solid tumor treatment. The immunosuppressive microenvironment of tumors affects CAR-T cells, limiting the treatment's effectiveness and safety. Therefore, enhancing CAR-T cell infiltration capacity and resolving the immunosuppressive responses within the tumor microenvironment could boost the anti-tumor effect. Specific strategies include structurally altering CAR-T cells combined with targeted therapy, radiotherapy, or chemotherapy. Overall, monitoring the tumor microenvironment and the status of CAR-T cells is beneficial in further investigating the viability of such strategies and advancing CAR-T cell therapy.© 2024. The Author(s).